title: Nep1 Experiment 1

city: Beltsville

first: Hanhong

last: Bae

state: MD

address: 10300 Baltimore Ave

institute: USDA-ARS-PSI

description: In order to study the Nep1 responsive genes in Arabidopsis, experiments were performed with the Affymetrix GeneChip Arabidopsis ATH1 Genome Array (Santa Clara, CA; Cat # 900385).  Seven-day old Arabidopsis seedlings were exposed to Nep1 (10 ug/mL) treatment or using sterilized, deionized H2O as a control for 30 min.  Two independent biological replications were conducted using two independent samples and two microarrays.

data_processing: The probe array was scanned using GeneArray scanner with 570 nm wavelength and 3 um pixel value, which was controlled by GeneChip Operating Software (GCOS 1.2).  The data image file was analyzed for probe intensities.  The output of the GCOS was further analyzed using Microsoft Excel (Microsoft, Redmond, WA).  Differences in transcript abundance (fold change) were calculated and fold change was accepted only if the corresponding change call showed a significant change (I = increase and D = decrease), which was generated by GCOS.

label: Biotynalted cRNA

organism: Arabidopsis thaliana

source_name: 7 days old, MS liquid culture grown seedlings

extract_protocol: The harvested whole seedlings were ground to a fine powder under liquid nitrogen using a mortar and pestle.  Total RNA was extracted using a RNeasy mini kit (Qiagen, Valencia, CA) as described by the manufacturer and then purified with a RNeasy MinElute Cleanup Kit (Qiagen).

treatment_protocol: One-week old seedlings were exposed to Nep1 (10 ug/mL) treatment or using sterilized, deionized H2O as a control.  Seedlings were harvested after 30 min treatment, filtered through Whatman #1 filter paper (Whatman, Middlesex, UK), rinsed thoroughly with deionized water and were immediately frozen in liquid nitrogen.

tag: Columbia ecotype


title: Treatment: Vehicle; Time: 24 hrs; Repeat: 1

status: Public on Apr 11 2006

type: RNA

city: Palo Alto

first: Dmitri

middle: A

last: Kazmin

state: CA

address: 240 Pasteur Dr

department: Institute for Immunity, Transplantation and Infection

country: USA

institute: Stanford University

description:
A study of the SARM-regulated gene expression in LNCaP prostate carcinoma cells.
Treated with ethanol vehicle for 24 hrs.

data_processing: Standard Affymetrix scanning/normalization process

label: Biotin

molecule: polyA RNA

organism: Homo sapiens

source_name: LNCaP cells

treatment_protocol:
In this experiment LNCaP cells
were treated with Vehicle (ethanol),
DHT (10 nM) or RTI-66413-018 (100 nM).
Treatment was done for 6 and 24 hrs.
The entire experiment was repeated 3 times.

tag: LNCaP cells; Human, prostate carcinoma, metastasized to lymph node; Maintained in DMEM/8% charcoal-stripped serum for 3 days before treatment.


title: A2 set #008 Ad HVC Mix Type A

city: Durham

first: Osceola

last: Whitney

state: NC

address: Research Drive, Bryan Research Building, Room 401E

department: Neurobiology

institute: Duke University Medical Center

description: Animals were perfused with 4% paraformaldehyde, brains removed, processed further in fixative, 120um sagittal slices cut of the right hemisphere, and under a dissecting microscope, vocal nuclei dissected (HVC, RA, Area X, LMAN); the left hemisphere was used for in-situ hybridization verification of egr-1 induction. From the dissected vocal nuclei, total RNA was isolated, linearly amplified, converted to sense cDNA labeled with Cy3 or Cy5 dyes, and hybridized to the microarrays. For details see Wada et al., (in preparation).

data_processing: LOG ratio of median defined by F635/F532 (not normalized).

molecule: total RNA

organism: Taeniopygia guttata

source_name: HVC, song behavior 60min

tag: A mix of HVC from brains of 3 singing adult male zebra finches. Cy-dye labeled probes were generated for vocal nuclei (HVC, RA, LMAN, and LAreaX) of silent (overnight) and singing birds (undirected, >30 bouts/h for 1hr).

source_name: HVC, quiet

tag: A mix of HVC from brains of 3 quiet adult male zebra finches. Cy-dye labeled probes were generated for vocal nuclei (HVC, RA, LMAN, and LAreaX) of silent (overnight) and singing birds (undirected, >30 bouts/h for 1hr).


title: Treatment: vehicle; time: 6 hours; repeat: 1

description: Vehicle control used to compare similar samples treated with DHT or RTI-6413-018

treatment_protocol:
In this experiment LNCaP cells
were treated with Vehicle (ethanol),
DHT (10 nM) or RTI-6413-018 (100 nM).
Treatment was done for 6 and 24 hrs.
The entire experiment was repeated 3 times.


title: Treatment: vehicle; time: 24 hrs; repeat: 1; chip B

description:
A study of the SARM-regulated gene expression in LNCaP prostate carcinoma cells.
Treated with vehicle for 24 hrs.

label: biotin


title: Treatment: DHT; time: 6 hrs; repeat: 1; chip B

description:
A study of the SARM-regulated gene expression in LNCaP prostate carcinoma cells.
Treated with DHT for 6 hrs


title: Nep1 Experiment 2


title: Treatment: RTI-6413-018; time: 24 hrs; repeat: 1

description:
A study of the SARM-regulated gene expression in LNCaP prostate carcinoma cells.
SARM-treated for 6 hrs


title: Treatment: RTI-6413-018; time: 6 hrs; repeat: 1

description:
A study of the SARM-regulated gene expression in LNCaP prostate carcinoma cells.
SARM treatment for 6 hrs.


title: Treatment: RTI-6413-018; time: 6 hrs; repeat: 2

description:
A study of the SARM-regulated gene expression in LNCaP prostate carcinoma cells.
Treated with SARM for 6 hrs.


title: Treatment: DHT; time: 6 hrs; repeat: 1

description: DHT-treated for 6 hrs


title: Human_macrophages_hypoxia_repB

city: Göteborg

first: Per-Arne

last: Svensson

country: Sweden

institute: Internal Medicine

description: Total RNA was isolated with the RNeasy kit (Qiagen) from macrophages incubated at normoxia (21% oxygen) or hypoxia (0% oxygen) for 24 h. Two μg RNA from 4 donors incubated at normoxia and 4 donors at hypoxia was pooled respectively and these 2 pools were used for the target preparation and analyzed on duplicate DNA microarrays (Hu95A; Affymetrix).

data_processing: MAS 5, signal algorithm, global scaling (target intensity 500)

label: PE

source_name: Human monocyte-derived macrophages

extract_protocol: Total RNA was isolated with the RNeasy kit (Qiagen).

tag: Human mononuclear cells were isolated by Ficoll-Paque centrifugation in a discontinuous gradient from buffy coats from healthy blood donors. Cells were differentiated in macrophage-SFM medium supplemented with 70 U/ml human granulocyte macrophage colony-stimulating factor. After 3 days, the medium was changed to macrophage-SFM without GM-CSF and cells were cultured up to 8 days


title: A2 set #003 Ad HVC Mix Type B

data_processing: LOG ratio of median defined by F532/F635 (not normalized)

tag: A mix of HVC from brains of 3 quiet adult male zebra finches. Cy-dye labeled probes were generated for vocal nuclei (HVC, RA, LMAN, and LAreaX) of silent (overnight) and singing birds (undirected, >30 bouts/h for 1hr).  For details see Wada et al., (in preparation).


title: Control Experiment 2

growth_protocol: Approximately 100 sterilized seeds were transferred to sterile 125-mL Erlenmeyer flasks containing 20 mL of 1X MS basal salts supplemented with 1X vitamin B5, and 0.1 mM MES-NaOH (pH 5.7) buffer.  Seedlings were grown in controlled environment chambers and the flasks were continuously agitated with a rotary shaker for 7 days.  Seedlings were grown in growth chamber at 22°C for 7 days under fluorescent lights providing 150 ± 10 µmol /m2/s photosynthetically active radiation (PAR) with 16-h days.

treatment_protocol: One-week old seedlings were exposed to Nep1 (10 g mL-1) treatment or using sterilized, deionized H2O as a control.  Seedlings were harvested after 30 min treatment, filtered through Whatman #1 filter paper (Whatman, Middlesex, UK), rinsed thoroughly with deionized water and were immediately frozen in liquid nitrogen.


title: Treatment: vehicle; time: 6 hrs; repeat: 1; chip B

description:
A study of the SARM-regulated gene expression in LNCaP prostate carcinoma cells.
Treated with vehicle for 6 hrs


title: A2 set #009 Ad RA Mix Type A

description: Animals were perfused with 4% paraformaldehyde, brains removed, processed further in fixative, 120um sagittal slices cut of the right hemisphere, and under a dissecting microscope, vocal nuclei dissected (HVC, RA, Area X, LMAN); the left hemisphere was used for in-situ hybridization verification of egr-1 induction. From the dissected vocal nuclei, total RNA was isolated, linearly amplified, converted to sense cDNA labeled with Cy3 or Cy5 dyes, and hybridized to the microarrays. For details see Wada et al., (in preparation)

data_processing: LOG ratio of median defined by 635/532 (not normalized).

source_name: RA, Song behavior 60min

tag: A mix of RA from brains of 3 singing adult male zebra finches. Cy-dye labeled probes were generated for vocal nuclei (HVC, RA, LMAN, and LAreaX) of silent (overnight) and singing birds (undirected, >30 bouts/h for 1hr).

source_name: RA, quiet

tag: A mix of RA from brains of 3 quiet adult male zebra finches. Cy-dye labeled probes were generated for vocal nuclei (HVC, RA, LMAN, and LAreaX) of silent (overnight) and singing birds (undirected, >30 bouts/h for 1hr).


title: A2 set #005 Ad MAN Mix Type B

data_processing: LOG ratio of median defined by 532/635 (not normalized)

source_name: MAN, quiet

tag: A mix of MAN from brains of 3 singing adult male zebra finches. Cy-dye labeled probes were generated for vocal nuclei (HVC, RA, LMAN, and LAreaX) of silent (overnight) and singing birds (undirected, >30 bouts/h for 1hr).

source_name: MAN, Song behavior 60min


title: Control Experiment 1

data_processing: The probe array was scanned using GeneArray scanner with 570 nm wavelength and 3 m pixel value, which was controlled by GeneChip Operating Software (GCOS 1.2).  The data image file was analyzed for probe intensities.  The output of the GCOS was further analyzed using Microsoft Excel (Microsoft, Redmond, WA).  Differences in transcript abundance (fold change) were calculated and fold change was accepted only if the corresponding change call showed a significant change (I = increase and D = decrease), which was generated by GCOS.

label: Biotinylated cRNA

growth_protocol: Approximately 100 sterilized seeds were transferred to sterile 125-mL Erlenmeyer flasks containing 20 mL of 1X MS basal salts supplemented with 1X vitamin B5, and 0.1 mM MES-NaOH (pH 5.7) buffer.  Seedlings were grown in controlled environment chambers and the flasks were continuously agitated with a rotary shaker for 7 days.  Seedlings were grown in growth chamber at 22°C for 7 days under fluorescent lights providing 150 ± 10 µmol /m2/s1 photosynthetically active radiation (PAR) with 16-h days.


title: Treatment: DHT; Time: 24 hrs; repeat: 1

description:
A study of the SARM-regulated gene expression in LNCaP prostate carcinoma cells.
DHT-treated for 24 hrs


title: A2 set#012 Ad RA Single Type A

tag: RA from brain of a singing adult male zebra finch. Cy-dye labeled probes were generated for vocal nuclei (HVC, RA, LMAN, and LAreaX) of silent (overnight) and singing birds (undirected, >30 bouts/h for 1hr).

tag: RA from brain of  a quiet adult male zebra finch. Cy-dye labeled probes were generated for vocal nuclei (HVC, RA, LMAN, and LAreaX) of silent (overnight) and singing birds (undirected, >30 bouts/h for 1hr).


title: A2 set #025 Ad HVC Single Type B

data_processing: LOG ratio of median defined by F532/F635 (not normalized).

tag: HVC from brain of a quiet adult male zebra finch. Cy-dye labeled probes were generated for vocal nuclei (HVC, RA, LMAN, and LAreaX) of silent (overnight) and singing birds (undirected, >30 bouts/h for 1hr).

source_name: HVC, singing behavior 60min

tag: HVC from brain of a singing adult male zebra finch. Cy-dye labeled probes were generated for vocal nuclei (HVC, RA, LMAN, and LAreaX) of silent (overnight) and singing birds (undirected, >30 bouts/h for 1hr).


title: B27LPSvsCLPS GA8 GR

status: Public on Apr 10 2006

city: Cambridge

first: Giles

last: Yeo

address: CIMR, Addenbrookes Hospital

department: Clinical Biochemistry

country: United Kingdom

institute: University of Cambridge

description: Data were imported into GeneSpringTM 7.2 (Silicon Genetics) for analysis and normalization was performed using the Loess algorithm. Identification of genes with ratios statistically significantly different from 1 was performed using a t-test at the 95% confidence level.

hyb_protocol: For each set of conditions tested, duplicate and dye-swap hybridizations were performed. Labeled targets were resuspended in 30μl of hybridization buffer (40% formamide, 5x SSC, 5x Denhardt's solution, 1 mM sodium pyrophosphate, 50 mM Tris pH 7.4, 0.1% SDS) together with 2μg human Cot1 DNA (Invitrogen), denatured at 95°C for 5 min, incubated at 50°C for 5 min and then centrifuged at 13,000 r.p.m. for 5 min before being applied to the arrays. Hybridizations were performed under a coverslip at 50°C in a humidified chamber for 16 h. Following hybridization, slides were washed twice in 2x SSC for 10 min, twice in 0.1x SSC/0.1% SDS for 5 min and finally twice in 0.1x SSC for 5 min; all washes were performed at RT. After washing, slides were dried by centrifugation at 2000g for 3 min.

scan_protocol: Arrays were scanned on an Agilent G2565 scanner according to manufacturer’s instructions. Raw image data were extracted using BlueFuse (BlueGnome Ltd., Cambridge UK).

source_name: B27 U937 LPS Treated Cy3

label_protocol: cDNA was amplified from total RNA using template-switching PCR and labeled with Cy3 or Cy5 dyes as previously described (Petalidis et al, 2003, NAR).  The amplified cDNA was purified on an AutoSeq G-50 column (Amersham Biosciences) according to the supplied protocol.  1μg of the amplified cDNA was labeled using the BioPrimeTM DNA labelling system (Invitrogen) in a 100μl reaction as described by the manufacturer, CyDyeTM5-dCTP or CyDyeTM3-dCTP (Amersham Biosciences). The labelled products were purified on an AutoSeq G-50 columns, the Cy5 and Cy3 samples were then pooled and ethanol precipitated.

growth_protocol: Transfectants were cultured in RPMI 1640 (Invitrogen, U.K) supplemented with 10% fetal bovine serum (Sigma U.K), 2mM glutamine and 20mM Hepes in a humidified 5% CO2 atmosphere at 37oC.

extract_protocol: Total RNA was extracted from U937 cell lines using RNA STAT60TM (Tel-Test “B” Inc) and further purified using RNeasyTM columns (Qiagen).

treatment_protocol: U937 cells were differentiated with PMA (Sigma, U.K) (10ng/ml) for 24 hours followed by 4 hour culture with or without 500ng/ml LPS.

tag: HLA-B27 stable U937 transfectants LPS treated Cy3 labelled

source_name: C U937 LPS Treated Cy5

tag: pRc vector stable U937 transfectants LPS Treated Cy5 labelled


title: B27LPSvsC GA9 GR

data_processing: Raw image data were extracted using BlueFuse (BlueGnome Ltd., Cambridge UK).

source_name: C U937 Cy5

tag: pRc vector stable U937 transfectants Cy5 labelled


title: 35S:AP1-GR ap1 cal  4d vs. 5d set3

city: Pasadena

first: Frank

last: Wellmer

address: 1200 E. California Blvd.

department: Biology 156-29

institute: California Institute of Technology

description: Plants were grown on a soil:vermiculite:perlite mixture under constant illumination at 20°C. Immediately after the onset of bolting, the inflorescences of 35S:AP1-GR ap1 cal plants were treated with a solution containing 1 μM dexamethasone (Sigma-Aldrich, St. Louis, MO, USA), 0.01% (v/v) ethanol, and 0.015% (v/v) Silwet L-77. For each time point, tissue from ~25 plants was collected using jewelers forceps. Tissue was removed as close to the surface of the inflorescence as possible to ensure an enrichment of meristematic cells.

data_processing: Data were processed in Rosetta Resolver v4.0

source_name: 35S:AP1-GR ap1 cal  4d

tag: Material was derived from inflorescences of 35S:AP1-GR ap1 cal plants, 4d after activation of the AP1-GR fusion protein with dexamethasone

source_name: 35S:AP1-GR ap1 cal  5d

tag: Material was derived from inflorescences of 35S:AP1-GR ap1 cal plants, 5d after activation of the AP1-GR fusion protein with dexamethasone


title: CLPSvsC GA8 RG

tag: pRc vector stable U937 transfectants LPS treated Cy5 labelled

source_name: C U937 Cy3

tag: pRc vector stable U937 transfectants Cy3 labelled


title: 35S:AP1-GR ap1 cal  3d vs. 4d set3

source_name: 35S:AP1-GR ap1 cal  3d

tag: Material was derived from inflorescences of 35S:AP1-GR ap1 cal plants, 3d after activation of the AP1-GR fusion protein with dexamethasone


title: B27LPSvsCLPS GA9 GR


title: B27LPSvsC GA6 RG

source_name: B27 U937 LPS Treated Cy5

tag: HLA-B27 stable U937 transfectants LPS treated Cy5 labelled


title: CLPSvsC GA9 RG


title: 35S:AP1-GR ap1 cal  3d vs. 4d set4


title: B27LPSvsC GA6 GR


title: Leafdiscs_DTT_control1

city: Potsdam

first: Joost

middle: T.

last: van Dongen

address: Am Muehlenberg 1

country: Germany

institute: Max Planck Institute of Molecular Plant Physiology

description: source leaf discs of Wild type Arabidopsis thaliana Col0 rosette plants.

hyb_protocol: standard Affymetrix protocol

scan_protocol: standard Affymetrix protocol

source_name: Leaf

label_protocol: 10µg total RNA was biotin labelled

growth_protocol: Plants were grown in a phytotron with a 14h day / 10h night. Temperature: 20°C / 16°C. Humidity: 60% / 75%. Lightintensity: .

extract_protocol: Total RNA extraction using TRIzol Total RNA Isolation Reagent, according to the protocol supplied by the manufacturer GibcoBRL Life-Technologies.

treatment_protocol: Source leaf discs taken at the end of the night from non-flowering plants. Discs were incubated in the dark for one hour in 2mM MES buffer, pH 6.5 with (treatment) or without (control) 5mM dithiotreitol (DTT). After incubation discs were snap-frozen in liquid nitrogen.

tag: control (-DTT) to DTT treatment (+DTT) Leafdiscs_DTT_treatment1

tag: ecotype

tag: developmental stage

value: full grown leaves of non-flowering plants


title: B27LPSvsC GA8 GR


title: Leafdiscs_DTT_treatment2

description: source leaf discs of Wild type Arabidopsis thaliana Col0 rosette plants

tag: treatment (+DTT) belonging to control (-DTT) Leafdiscs_DTT_control2


title: CLPSvsC GA6 RG


title: 35S:AP1-GR ap1 cal  2d vs. 3d set3

source_name: 35S:AP1-GR ap1 cal  2d

tag: Material was derived from inflorescences of 35S:AP1-GR ap1 cal plants, 2d after activation of the AP1-GR fusion protein with dexamethasone


title: 35S:AP1-GR ap1 cal  3d vs. 4d set2


title: 35S:AP1-GR ap1 cal  4d vs. 5d set1


title: B27LPSvsC GA8 RG


title: 35S:AP1-GR ap1 cal  2d vs. 3d set4


title: 35S:AP1-GR ap1 cal  3d vs. 4d set1


title: CLPSvsC GA9 GR

source_name: C U937 LPS Treated Cy3

tag: pRc vector stable U937 transfectants LPS treated Cy3 labelled


title: B27LPSvsCLPS GA9 RG

tag: pRc vector stable U937 transfectants LPS Treated Cy3 labelled


title: B27LPSvsC GA9 RG


title: 35S:AP1-GR ap1 cal  2d vs. 3d set2


title: 35S:AP1-GR ap1 cal  1d vs. 2d set2

source_name: 35S:AP1-GR ap1 cal  1d

tag: Material was derived from inflorescences of 35S:AP1-GR ap1 cal plants, 1d after activation of the AP1-GR fusion protein with dexamethasone


title: CLPSvsC GA8 GR


title: 35S:AP1-GR ap1 cal  1d vs. 2d set3


title: 35S:AP1-GR ap1 cal  1d vs. 2d set4


title: 35S:AP1-GR ap1 cal  2d vs. 3d set1


title: MCL patient 05-109

type: genomic

city: Bellinzona

first: Francesco

last: Bertoni

state: Ticino

address: Via Vela 6

department: Experimental Oncology

country: Switzerland

institute: Institute of Southern Switzerland

description: human B cell lymphoma

hyb_protocol: standard Affymetrix procedures using Fluidics Station 400

scan_protocol: standard Affymetrix procedures using GeneChip Scanner 3000

data_processing: Affymetrix GeneChip GCOS 1.1, GTYPE (with CNAT 3.0)

molecule: genomic DNA

source_name: MCL patient 05-109

label_protocol: standard Affymetrix protocol starting from 250 ng of DNA.

extract_protocol: genomic DNA was extracted using the Qiagen DNA Mini kit (Qiagen, Hilden, Germany) dissolved in reduced EDTA TE buffer.

tag: human mantle cell lymphoma clinical sample


title: Leafdiscs_DTT_treatment1

tag: treatment (+DTT) belonging to control (-DTT) Leafdiscs_DTT_control1


title: CLPSvsC GA6 GR

tag: pRc vector stable U937 transfectants Cy5 labelled


title: B27vsC GA9 RG

treatment_protocol: U937 cells were differentiated with PMA (Sigma, U.K) (10ng/ml) for 24 hours followed by 4 hour culture.

tag: HLA-B27 stable U937 transfectants Cy5 labelled


title: B27LPSvsCLPS GA6 GR

tag: HLA-B27 stable U937 transfectants LPS treated Cy3 labelled

tag: pRc vector stable U937 transfectants LPS Treated Cy5 labelled


title: B27vsC GA8 RG

tag: pRc vector stable U937 transfectants Cy3 labelled


title: B27vsC GA9 GR

tag: HLA-B27 stable U937 transfectants Cy3 labelled


title: MCL patient 04-282

description: human B cell lymphoma

source_name: MCL patient 04-282


title: Leafdiscs_DTT_control2

tag: control (-DTT) to DTT treatment (+DTT) Leafdiscs_DTT_treatment2


title: 35S:AP1-GR ap1 cal  1d vs. 2d set1


title: MCL patient 05-107

description: human B cell lymphoma

source_name: MCL patient 05-107


title: MCL patient 04-276

description: human B cell lymphoma

source_name: MCL patient 04-276


title: MCL patient 04-275

description: human B cell lymphoma

source_name: MCL patient 04-275


title: MCL patient 05-108

description: human B cell lymphoma

source_name: MCL patient 05-108


title: MCF7 + 5-FU IC80 48H B

status: Public on Apr 07 2006

city: Bron

first: Hector

last: Hernandez-Vargas

state: Rhone

address: 36 bis Rue de la Batterie

country: France

institute: Genomics Consulting

description: Human breast carcinoma cell line MCF7, cultured in DMEM with Glutamax-1 supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and 0.4% fungizone. Passaged by trypsinization.

data_processing: GenePix Pro 5.0

source_name: MCF7 cells, 5-fluorouracil IC80, 48 hours, Cy3

source_name: Universal Human Reference RNA


title: B27vsC GA6 GR

source_name: C U937 Cy5


title: 35S:AP1-GR ap1 cal  0d vs. 1d set3

source_name: 35S:AP1-GR ap1 cal  0d

tag: Material was derived from inflorescences of 35S:AP1-GR ap1 cal plants, 0d after activation of the AP1-GR fusion protein with dexamethasone


title: MCF7 + 5-FU IC80 24H B

source_name: MCF7 cells, 5-fluorouracil IC80, 24 hours, Cy3


title: B27vsC GA6 RG

source_name: C U937 Cy3


title: MCF7 + 5-FU IC50 24H B

source_name: MCF7 cells, 5-fluorouracil IC50, 24 hours, Cy5

source_name: Universal Human Reference RNA, Cy3


title: MCL patient 04-273

description: human B cell lymphoma

source_name: MCL patient 04-273


title: A2 set#014 Ad RA Single Type B

data_processing: LOG ratio of median defined by 532/635 (not normalized).

source_name: RA, quiet

tag: RA from brain of a quiet adult male zebra finch. Cy-dye labeled probes were generated for vocal nuclei (HVC, RA, LMAN, and LAreaX) of silent (overnight) and singing birds (undirected, >30 bouts/h for 1hr).

source_name: RA, Song behavior 60min

tag: RA from brain of a singing adult male zebra finch. Cy-dye labeled probes were generated for vocal nuclei (HVC, RA, LMAN, and LAreaX) of silent (overnight) and singing birds (undirected, >30 bouts/h for 1hr).


title: MCL patient 04-274

description: human B cell lymphoma

source_name: MCL patient 04-274


title: MCF7 CONTROL IC80 B

source_name: MCF7 cells, no treatment, Cy3


title: MCL patient 04-272

description: human B cell lymphoma

source_name: MCL patient 04-272


title: MCF7 + 5-FU IC80 8H B

source_name: MCF7 cells, 5-fluorouracil IC80, 8 hours, Cy3


title: 35S:AP1-GR ap1 cal  0d vs. 1d set1

description:
Plants were grown on a soil:vermiculite:perlite mixture under constant illumination at 20°C. Immediately after the onset of bolting, the inflorescences of 35S:AP1-GR ap1 cal plants were treated with a solution containing 1 μM dexamethasone (Sigma-Aldrich, St. Louis, MO, USA), 0.01% (v/v) ethanol, and 0.015% (v/v) Silwet L-77. For each time point, tissue from ~25 plants was collected using jewelers forceps. Tissue was removed as close to the surface of the inflorescence as possible to ensure an enrichment of meristematic cells.
mRNA from total RNA preparations was amplified by in vitro transcription, so that amino-allyl-UTP was incorporated into the aRNA. Subsequently, fluorescent dyes were coupled to the aRNA.

source_name: 35S:AP1-GR ap1 cal  1d


title: B27vsC GA8 GR


title: MCL patient 04-277

description: human B cell lymphoma

source_name: MCL patient 04-277


title: B27LPSvsCLPS GA6 RG

source_name: B27 U937 LPS Treated Cy5

tag: HLA-B27 stable U937 transfectants LPS treated Cy5 labelled

source_name: C U937 LPS Treated Cy3


title: 35S:AP1-GR ap1 cal  0d vs. 1d set4


title: MCF7 + 5-FU IC80 48H

description: Human breast carcinoma cell line MCF7 cultured in DMEM with Glutamax-1, supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and 0.4% fungizone. Cells passaged by trypsinization.

source_name: MCF7 cells, 5-fluorouracil IC80, 48 hours, Cy5


title: MCF7 +5-FU IC50 8H B

source_name: MCF7 cells, 5-fluoruoracil IC50, 8 hours, Cy5


title: MDA-MB-435 + 5-FU 24H

description: Human breast carcinoma cell line MDA-MB-435, cultured in DMEM with Glutamax-1, supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and 0.4% fungizone. Cells were grown and passaged by trypsinization.

source_name: MDA-MB-435 cells, 5-fluorouracil, 24 hours

source_name: Universal Human Reference RNA


title: MDA-MB-435 + 5-FU 8H

source_name: MDA-MB-435 cells, 5-Fluorouracil 8 hours


title: MDA-MB-435 CONTROL

source_name: MDA-MB-435 cells, no treatment, Cy5

source_name: Universal Human Reference RNA, Cy3


title: MCF7 CONTROL IC80 A

source_name: MCF7 cells, no treatment, Cy5


title: MCF7 + 5-FU IC50 24H

source_name: MCF7 cells, 5-fluorouracil IC50, 24 hours, Cy5


title: MCF7 + 5-FU IC80 8H

source_name: MCF7 cells, 5-fluorouracil IC80, 8 hours, Cy5


title: 35S:AP1-GR ap1 cal  0d vs. 1d set2

source_name: 35S:AP1-GR ap1 cal  0d


title: B27LPSvsCLPS GA8 RG


title: MCF7 + 5-FU IC50 8H

source_name: MCF7 cells, 5-fluorouracil IC50, 8 hours, Cy5


title: MCF7 + 5-FU IC80 24H

source_name: MCF7 cells, 5-fluorouracil IC80, 24 hours, Cy5


title: flbD vs CB15N (rep 1)

status: Public on Apr 06 2006

first: Michael

last: Laub

state: MA

address: 31 Ames St.

institute: MIT

description: flbD deletion vs. wild type (rep 1)

data_processing: raw data

organism: Caulobacter vibrioides

source_name: flbD deletion

tag: synonym

value: Caulobacter crescentus

tag: flbD deletion

tag: CB15N wild type


title: MDA-MB-435, + 5-FU 48H

source_name: MDA-MB-435 cells, 5-fluorouracil 48 hours


title: flbD vs. CB15N (rep 2)

description: flbD deletion vs. wild type (rep 2)


title: rpoN vs. CB15N (rep 1)

description: rpoN disruption vs. wild type (rep 1)


title: MCF7 CONTROL IC50 B


title: MCF7 CONTROL IC50 A


title: MCF7 + 5-FU IC50 48H

source_name: MCF7 cells, 5-fluorouracil IC50, 48 hours, Cy5


title: tacA vs. CB15N (rep 2)

description: tacA deletion vs. wild type (rep 2)

source_name: tacA deletion

tag: tacA deletion


title: rpoN vs. CB15N (rep 2)

description: rpoN disruption vs. wild type (rep 2)


title: tDEA003.CEL

city: Houston

first: Chad

last: Creighton

state: TX

address: One Baylor Plaza, Mail Stop: BCM305

department: Biostatistics, Ducan Cancer Center

institute: Baylor College of Medicine

description: MCF-7 co-transfected with constituitively active MEK

data_processing: RMAExpress version 0.3

tag: MCF-7 breast cancer cells


title: tDEA006.CEL

description: MCF-7 co-transfected with constituitively active erbB-2


title: tDEA002.CEL


title: tacA vs. CB15N (rep 3)

description: tacA deletion vs. wild type (rep 3)


title: tacA vs. CB15N (rep 1)

description: tacA deletion vs. wild type (rep 1)


title: CC1114 vs. CB15N (rep 3)

description: CC1114 deletion vs. wild type (rep 3)

source_name: CC1114 deletion

tag: CC1114 deletion


title: CC1114 vs. CB15N (rep 4)

description: CC1114 deletion vs. wild type (rep 4)


title: tDEA001.CEL


title: tDEA005.CEL


title: CC1114 vs. CB15N (rep 2)

description: CC1114 deletion vs. wild type (rep 2)

source_name: CB15N wild type


title: CC1114 vs. CB15N (rep 1)

description: CC1114 deletion vs. wild type (rep 1)


title: tDEA004.CEL


title: 35S:AP1-GR ap1 cal  4d vs. 5d set4

source_name: 35S:AP1-GR ap1 cal  5d

tag: Material was derived from inflorescences of 35S:AP1-GR ap1 cal plants, 5d after activation of the AP1-GR fusion protein with dexamethasone

source_name: 35S:AP1-GR ap1 cal  4d

tag: Material was derived from inflorescences of 35S:AP1-GR ap1 cal plants, 4d after activation of the AP1-GR fusion protein with dexamethasone


title: CC0138 vs. CB15N (rep2)

description: CC0138 deletion vs. wild type (rep 2)

source_name: CC0138 deletion

tag: CC0138 deletion strain


title: CC0138 vs. CB15N

description: CC0138 deletion vs. wild type (rep 1)

tag: CC0138 deletion


title: Normal breast vs breast tumor (I304)

status: Public on Apr 05 2006

type: other

city: Research Triangle Park

middle: D.

last: Mattie

address: Five Moore Drive

department: Genomics Research

institute: GlaxoSmithKline

description: Quantitations are based on the images (ratios of median fluorescence intensity were the primary study measurements). Genepix 3.0 produces both feature and background intensity and ratio measurements for the Cy3 and Cy5 channels and notes if data are flagged by the analyst.

hyb_protocol: Briefly, 10 ng of enriched miRNA was amplified using the SenseAmp Plus protocol for miRNA from Genisphere Inc. 500 ng of amplified miRNA was labeled and hybridized in the supplied 2X SDS based hybridization buffer to the arrays at 46 degrees Celsius for 16 hours in a Hybex hybridization oven (SciGene). Arrays were washed as follows: Cover slips were floated off in wash 1 (2X SSC, 0.2% SDS pre-warmed to 42 degrees Celsius), arrays were then washed in pre-warmed wash #1 for 15 minutes, rinsed in wash #2 (2X SSC) for 10 minutes at room temperature, and rinsed in wash #3 (0.2X SSC) for 10 minutes at room temperature. Slides were then dried in a centrifuge. The 3DNA Capture Reagent was then hybridized to the arrays for 4 hours at 60 degrees Celsius. Washes were performed as above with the exception that wash #1 was pre-warmed to 60 degrees Celsius.

scan_protocol: Images were acquired using an Axon 4000b confocal laser scanner with Genepix 3.0 software (Axon, Foster City, CA).

data_processing: Only Genepix median ratios for non-flagged spots were used for the analysis. Genepix data was uploaded to the NOMAD relational database (http://derisilab.ucsf.edu), median ratio information was downloaded after linear normalization of Cy3 and Cy5 signals (equal average intensity of each fluorescent channel). Data were formatted for the Cluster (http://rana.lbl.gov) algorithm, which was used after log base 2 transformation of ratios, and filtering to exclude genes flagged in more than 20% of the arrays.

molecule: other

source_name: Normal breast

label_protocol: Samples were labeled using the Array900 miRNA RT kit protocol from Genisphere Inc.  500 ng of amplified material was labeled.

extract_protocol: MicroRNA was isolated from the total RNA using the mirVana microRNA isolation kit from Ambion

tag: Commercially obtained RNA from normal breast tissue of a 55 year old female

source_name: breast tumor (I304)

extract_protocol: MicroRNA was isolated from Trizol extracted total RNA using the mirVana microRNA isolation kit from Ambion

tag: breast tumor biopsy


title: Normal breast vs breast tumor (I388)

source_name: breast tumor (I388)


title: 35S:AP1-GR ap1 cal  4d vs. 5d set2


title: Normal breast vs breast tumor (I400)

tag: Commercially obtained RN from normal breast tissue of 55 year old female

source_name: breast tumor (I400)


title: Normal breast vs breast tumor (I282)

source_name: breast tumor (I282)


title: Normal breast vs tumor (I214)

source_name: breast tumor (I214)


title: Normal breast vs breast tumor (I80)

source_name: breast tumor (I80)


title: Normal breast vs breast tumor (I155)

source_name: breast tumor (I155)


title: Normal breast vs breast tumor (I196)

source_name: breast tumor (I196)


title: Normal breast vs breast tumor (I55)

source_name: breast tumor (I55)


title: Normal breast vs breast tumor (I427)

source_name: breast tumor (I427)


title: Normal breast vs breast tumor (I359)

hyb_protocol: Briefly, 10 ng of enriched miRNA was amplified using the SenseAmp Plus procedure for microRNA from Genisphere Inc.  500 ng of amplified miRNA was labeled and hybridized in the supplied 2X SDS based hybridization buffer to the arrays at 46 degrees Celsius for 16 hours in a Hybex hybridization oven (SciGene). Arrays were washed as follows: Cover slips were floated off in wash 1 (2X SSC, 0.2% SDS pre-warmed to 42 degrees Celsius), arrays were then washed in pre-warmed wash #1 for 15 minutes, rinsed in wash #2 (2X SSC) for 10 minutes at room temperature, and rinsed in wash #3 (0.2X SSC) for 10 minutes at room temperature. Slides were then dried in a centrifuge. The 3DNA Capture Reagent was then hybridized to the arrays for 4 hours at 60 degrees Celsius. Washes were performed as above with the exception that wash #1 was pre-warmed to 60 degrees Celsius.

extract_protocol: MicroRNA was isolated from the normal breast tissue using the mirVana microRNA isolation kit from Ambion

source_name: breast tumor (I359)

extract_protocol: MicroRNA was isolated from breast tissue total RNA using the mirVana microRNA isolation kit from Ambion


title: Normal breast vs tumor (I251)

tag: Commercially obtained RNA from normal breast tumor of a 55 year old female

source_name: breast tumor (I251)


title: Normal breast vs breast tumor (I99)

tag: Commercially obtained RNA from normal breast tissue of a 55 year old woman

source_name: breast tumor (I99)


title: Normal breast vs. breast tumor (I319)

source_name: breast tumor (I319)


title: Normal breast vs breast tumor (I97)

tag: Commercially obtained RNA from normal breast tissue of a 55 year old female.

source_name: breast tumor (I97)


title: Normal breast vs breast tumor (I5)

source_name: breast tumor (I5)


title: Normal breast vs breast tumor (I289)

source_name: Normal breast

source_name: breast tumor (I289)

tag: breast tumor biopsies


title: Normal breast vs breast tumor (I30)

source_name: breast tumor (I30)


title: Normal breast vs breast tumor (I272)

tag: Commercially obtained RNA from normal breast tissue from a 55 year old female

source_name: breast tumor (I272)


title: Normal prostate vs. needle core tumor

hyb_protocol: Briefly, 10 ng of enriched miRNA was amplified using a modification of the SenseAmp Plus protocol from Genisphere.  A total of 750 ng of amplified material was labeled and hybridized in the supplied 2X SDS based hybridization buffer to the arrays at 46 degrees Celsius for 16 hours in a Hybex hybridization oven (SciGene). Arrays were washed as follows: Cover slips were floated off in wash 1 (2X SSC, 0.2% SDS pre-warmed to 42 degrees Celsius), arrays were then washed in pre-warmed wash #1 for 15 minutes, rinsed in wash #2 (2X SSC) for 10 minutes at room temperature, and rinsed in wash #3 (0.2X SSC) for 10 minutes at room temperature. Slides were then dried in a centrifuge. The 3DNA Capture Reagent was then hybridized to the arrays for 4 hours at 60 degrees Celsius. Washes were performed as above with the exception that wash #1 was pre-warmed to 60 degrees Celsius.

source_name: Normal prostate

label_protocol: Samples were labeled using the Array900 miRNA RT kit protocol from Genisphere Inc.  A total of 750 ng of amplified material was labeled.

extract_protocol: MicroRNA was isolated from the prostate tissue by Ambion (mirVana Isolation kit)

tag: Commercially obtained RNA from prostate of 79 year old male

source_name: Needle core tumor

extract_protocol: MicroRNA was isolated from the needle core biopsy using the mirVana microRNA isolation kit from Ambion

tag: Needle core biopsy of the prostate, tumor with Gleason score 8, advanced prostate cancer


title: Normal prostate vs FNA prostate

source_name: FNA prostate

extract_protocol: MicroRNA was isolated from the fine needle aspirate using the mirVana microRNA isolation kit from Ambion

tag: Fine needle aspirate of a prostate cancer metastasis at the supraclavicular lymph node


title: Normal prostate vs. needle core transitional cell metaplasia

source_name: Needle core transitional cell metaplasia

tag: Needle core biopsy of the prostate, transitional cell metaplasia, precursory lesion


title: PC3vsLNCaP_rep6

hyb_protocol: Briefly, 200 ng of enriched miRNA was labeled and hybridized in the supplied 2X SDS based hybridization buffer to the arrays at 46 degrees Celsius for 16 hours in a Hybex hybridization oven (SciGene). Arrays were washed as follows: Cover slips were floated off in wash 1 (2X SSC, 0.2% SDS pre-warmed to 42 degrees Celsius), arrays were then washed in pre-warmed wash #1 for 15 minutes, rinsed in wash #2 (2X SSC) for 10 minutes at room temperature, and rinsed in wash #3 (0.2X SSC) for 10 minutes at room temperature. Slides were then dried in a centrifuge. The 3DNA Capture Reagent was then hybridized to the arrays for 4 hours at 60 degrees Celsius. Washes were performed as above with the exception that wash #1 was pre-warmed to 60 degrees Celsius.

source_name: PC3 cells

label_protocol: Samples were labeled using the Array900 miRNA RT kit protocol from Genisphere Inc.

growth_protocol: Standard growth conditions

extract_protocol: MicroRNA was isolated from the untreated PC3 cells using the mirVana microRNA isolation kit from Ambion

treatment_protocol: Untreated

tag: Untreated PC3 cells, hormone insensitive prostate cancer cell line

source_name: LNCaP cells

extract_protocol: MicroRNA was isolated from the untreated LNCaP cells using the mirVana microRNA isolation kit from Ambion

tag: Untreated LNCaP cells, hormone sensitive prostate cancer cells


title: PC3vsLNCaP amplified #3

hyb_protocol: Briefly, 10 ng of enriched miRNA was amplified using the SenseAmp Plus protocol for miRNA amplification from Genisphere Inc.  A total of 750 ng of amplified material was labeled and hybridized in the supplied 2X SDS based hybridization buffer to the arrays at 46 degrees Celsius for 16 hours in a Hybex hybridization oven (SciGene). Arrays were washed as follows: Cover slips were floated off in wash 1 (2X SSC, 0.2% SDS pre-warmed to 42 degrees Celsius), arrays were then washed in pre-warmed wash #1 for 15 minutes, rinsed in wash #2 (2X SSC) for 10 minutes at room temperature, and rinsed in wash #3 (0.2X SSC) for 10 minutes at room temperature. Slides were then dried in a centrifuge. The 3DNA Capture Reagent was then hybridized to the arrays for 4 hours at 60 degrees Celsius. Washes were performed as above with the exception that wash #1 was pre-warmed to 60 degrees Celsius.

source_name: Amplified PC3

treatment_protocol: Untreated cells

tag: Amplified PC3, hormone insensitive prostate cancer cells

source_name: Amplified LNCaP

tag: Amplified LNCaP, hormone sensitive prostate cancer cells


title: Normal prostate vs. PC3

tag: Commercially obtained RNA from normal prostate of a 79 year old male

treatment_protocol: Untreated PC3 cells


title: PC3vsLNCaP amplified #1

tag: Amplified PC3 cells, hormone insensitive prostate cancer cell line

tag: Amplified LNCaP cells, hormone sensitive prostate cancer cell line


title: PC3vsLNCaP_rep5

tag: Untreated PC3 cells, hormone insensitive prostate cancer cells

tag: Untreated LNCaP cells, hormone sensitive prostate cancer cell line


title: Normal prostate vs. LNCaP

tag: Commerically obtained RNA from prostate tissue from a 79 year old male


title: PC3vsLNCaP_rep4

tag: Untreated PC3 cells, hormone insenstive prostate cancer cell line


title: PC3vsLNCaP amplified #2


title: 2004-06-06 Cold

city: Richmond

first: Larry

middle: A.

last: Sonna

state: VA

address: 2020-I Timbers Hill Road

institute: Gene Expression Consulting

description: Background:  Moderate hypothermia (32oC for 12 – 72 hours) has therapeutic applications, but the mechanisms by which it affects cellular function are unclear.  We tested the hypothesis that moderate hypothermia produces broad changes in gene expression by human cells at the level of mRNA.

data_processing: CGOS 1.2

label: Phycoerythrin

source_name: THP-1 Cells in Culture x 24 hours at 32oC

label_protocol: Affymetrix

treatment_protocol: See Sonna et al., The effect of moderate hypothermia on gene expression by THP-1 cells:  A cDNA microarray study.  Physiological Genomics, submitted

tag: THP-1 Cells exposed to control (37oC) or hypothermic (32oC) conditions for 24 hours


title: PC3vsLNCaP_rep3


title: PC3vsLNCaP_rep2

source_name: LNCaP


title: Normal breast vs breast tumor (I52)

tag: Commercially obtained RNA from normal breast tissue of a 55 year old woman

source_name: breast tumor (I52)

tag: breast tumor biopsy


title: PC3vsLNCAP_rep1

tag: Untreated PC3 cells, hormone-insensitive prostate cancer cell line


title: 2004-06-03 PM Control

source_name: THP-1 Cells in Culture x 24 hours at 37oC


title: 2004-06-06 Control


title: 2003-12-02 Control

description:
Background:  Moderate hypothermia (32oC for 12 – 72 hours) has therapeutic applications, but the mechanisms by which it affects cellular function are unclear.  We tested the hypothesis that moderate hypothermia produces broad changes in gene expression by human cells at the level of mRNA.
Methods:  Acute monocytic leukemia THP-1 cells were incubated under control conditions (37oC) or moderate hypothermia (32oC) for 24 hours.  Cellular mRNA was extracted and a cold stress response was confirmed by examining the expression of the cold-inducible gene CIRBP by reverse transcription PCR (RT-PCR).  Gene expression analysis was performed on seven sets of samples with Affymetrix U133A chips, using established statistical methods.  Sequences were considered to be affected by cold if they showed statistically significant changes in expression and also met published post-hoc filter criteria (changes in geometric mean expression of 2-fold or greater and detection calls of “present” or “marginal” in at least half of the experiments).  The changes in expression of a select number of these sequences were further confirmed by PCR.
Results:  167 sequences met our prospectively defined criteria for a change in expression; 67 showed increases in expression and 100 showed decreases in expression.  Consistent with prior literature, the cold-inducible genes CIRBP and RBM3 showed increases in expression.  Functional categories affected by cold stress included genes involved in immune responses, cell growth, proliferation, and differentiation, and metabolism and biosynthesis.  Several heat shock proteins (HSPs) showed decreases in expression.
Conclusions:  Moderate hypothermia produces substantial changes in cellular gene expression, in categories potentially of importance to systemic function.  Interestingly, cold exposure without re-warming decreased the expression of several HSPs.  Our in vitro findings suggest that moderate hypothermia in vivo might produce physiologically important changes in gene expression by circulating leukocytes.

source_name: THP-1 cells in culture x 24 hours at 37oC

treatment_protocol: See Sonna et al., The effect of moderate hypothermia on gene expression by THP-1 cells A cDNA microarray study  Physiological Genomics 2006, submitted


title: 2003-12-04 Cold

treatment_protocol: See Sonna et al., The effect of moderate hypothermia on gene expression by THP-1 cells:  A cDNA microarray study


title: 3HA-TOR1 [I1954V + W2176R] -/+ 6 mM caffeine

status: Public on Apr 04 2006

city: Davis

first: Ted

last: Powers

address: One Shields Ave

department: Molecular and Cellular Biology

institute: UC Davis

data_processing: AMAD

organism: Saccharomyces cerevisiae

source_name: 3HA-TOR1 [I1954V + W2176R] minus caffeine

tag: SCD minus leucine media

source_name: 3HA-TOR1 [I1954V + W2176R] + 6 mM caffeine

tag: SCD minus leucine media + 6 mM caffeine


title: 2004-06-03 AM Control


title: 2004-01-30 Cold


title: Normal and TTT-treated Retina, Color Swap

city: Iruma

first: Keisuke

last: Mori

state: Saitama

address: 38 Morohongo, Moroyama

department: Department of Ophthalmology

country: Japan

institute: Saitama Medical University

description: A diode laser (IRIS Medical Instruments, Mountain View, CA) emitting at 810 nm wavelength mounted on a modified Haag-Streit slit lamp was used. Laser was applied at 50 mW for 60 seconds, using a 3 mm fixed spot size of this delivery system.Six nonoverlapping laser lesions were delivered to the fundus of each eye covering the visible posterior pole (TTT, transpupillary thermotherapy). Post TTT of 2-hour and also non-treated animals were sacrificed and the eyes were enucleated for RNA extraction. The anterior segment, lens and vitreous were carefully removed and immediately homogenized in TRIzol (Invitrogen, Carlsbad, CA).The total RNA was isolated by the acid guanidine thiocyanate-phenol-chloroform extraction method. Eextracted total RNA was quantified, and 75 μg was used in mRNA purification procedure (Dynabeads mRNA Purification Kit: DYNAL BIOTECH, Oslo, Norway). Dye-labeled cDNA was synthesized from 10 μg of poly(A)+RNA with Direct label Kit (Agilent Technologies, Palo Alto, CA). These dye-labeled cDNA were purified with QIA quick PCR Purification Kit (QIAGEN) and then hybridized with rat cDNA microarray. The microarray plates were scanned by a Microarray Scanner (Agilent Technologies) to detect and quantify the dye-signal intensity of each well.

data_processing: Local background correction and LOWESS normalization was accomplished by Feature Extraction Software (Agilent Technologies).

organism: Rattus norvegicus

source_name: TTT-treated Retina, 2-hr

tag: Strain

value: Brown Norway rats

tag: Age

value: 6 to 8 weeks

tag: TTT-treated Retina, 2-hour

source_name: Normal Retina

tag: Normal Retina


title: 2004-06-03 PM Cold


title: 3HA-TOR1 [I1954V + W2176R] -/+ 3 mM caffeine

source_name: 3HA-TOR1 [I1954V + W2176R] + 3 mM caffeine

tag: SCD minus leucine media + 3 mM caffeine


title: 3HA-TOR1 -/+ 6 mM caffeine

description: 3HA-TOR1 -/+ 6 mM caffeine

source_name: WT 3HA-TOR1 minus caffeine

source_name: WT 3HA-TOR1 plus 6 mM caffeine

tag: SCD minus leucine media plus 3 mM caffeine


title: 2004-02-04 Control


title: 3HA-TOR1 -/+ 9 mM caffeine

description: 3HA-TOR1 -/+ 9 mM caffeine

source_name: WT 3HA-TOR1 plus 9 mM caffeine

tag: SCD minus leucine media plus 9 mM caffeine


title: 2004-02-04 Cold


title: 3HA-TOR1 -/+ 3 mM caffeine

description: 3HA-TOR1 -/+ 3 mM caffeine

source_name: WT 3HA-TOR1 plus 3 mM caffeine


title: Sigma 2000 -/+ caffeine

description: Sigma 2000 -/+ 9 mM caffeine

source_name: minus caffeine

tag: WT grown in YPD

source_name: plus caffeine

tag: WT grown in YPD + caffeine


title: 2003-12-04 Control


title: 2004-01-30 Control


title: S288c -/+ caffeine

description: S288c -/+ 9 mM caffeine

tag: WT grown in YPD + 9 mM caffeine


title: Normal and TTT-treated Retina


title: 2004-06-03 AM Cold


title: 3HA-TOR1 [I1954V + W2176R] -/+ 9 mM caffeine

source_name: 3HA-TOR1 [I1954V + W2176R] + 9 mM caffeine

tag: SCD minus leucine media + 9 mM caffeine


title: W303a -/+ 6 mM caffeine

description: W303a -/+ 6 mM caffeine

tag: WT grown in YPD + 6 mM caffeine


title: S288c -/+ rapamycin

description: S288c -/+ 200 µg/ml rapamycin

source_name: minus rapamycin

source_name: plus rapamycin

tag: WT grown in YPD + 200 µg/ml rapamycin


title: MCF7 + 5-FU IC50 48H B

source_name: MCF7 cells, 5-fluorouracil IC50, 48 hours, Cy5

source_name: Universal Human Reference RNA, Cy3


title: W303a -/+ 0.3 mM caffeine

description: W303a -/+ 0.3 mM caffeine

tag: WT grown in YPD + 0.3 mM caffeine


title: Sigma 2000 -/+ rapamycin

description: Sigma 2000 -/+ 200 µg/ml rapamycin

tag: WT grown in YPD + rapamycin


title: W303a -/+ 9 mM caffeine

description: W303a -/+ 9 mM caffeine


title: W303a -/+ 1 mM caffeine

description: W303a -/+ 1 mM caffeine

tag: WT grown in YPD + 1 mM caffeine


title: W303a -/+ 3 mM caffeine

description: W303a -/+ 3 mM caffeine

tag: WT grown in YPD + 3 mM caffeine


title: W303a -/+ 200 µg/ml rapamycin

description: W303a -/+ 200 µg/ml rapamycin

source_name: plus 200 µg/ml rapamycin

tag: WT grown in YPD plus 200 µg/ml rapamycin


title: W303a -/+ 5 µg/ml rapamycin

description: W303a -/+ 5 µg/ml rapamycin

source_name: W303a -/+ 5 µg/ml rapamycin

tag: WT grown in YPD plus 5 µg/ml rapamycin


title: W303a -/+ 1 µg/ml rapamycin

description: W303a -/+ 1 µg/ml rapamycin

source_name: plus 1 µg/ml rapamycin

tag: WT grown in YPD plus 1 µg/ml rapamycin


title: MGU74Bv2_day3_GFP_rep3

status: Public on Apr 03 2006

first: Vamsi

middle: K.

last: Mootha

address: 7 Cambridge Center

department: Medical and Population Genetics

institute: Broad Institute

description: Gene expression data from cells on day3 after transduction with GFP.

hyb_protocol: standard Affymetrix procedures

scan_protocol: standard Affymetrix procedures

data_processing: The timecourse data from this platform were sample normalized via linear fit to the median scan, using Present genes.

organism: Mus musculus

source_name: myoblast (C2C12 cells) differentiated into myotubes

growth_protocol: C2C12 cells were cultured in DMEM containing 10% calf serum. They were then cultured in DMEM containing 2% heat-inactivated bovine calf serum for 3 days to induce differentiation into myotubes.

tag: Cell line


title: MGU74Bv2_day2_GFP_rep3

description: Gene expression data from cells on day2 after transduction with GFP.


title: MGU74Bv2_day2_PGC1a_rep3

description: Gene expression data from cells on day2 after transduction with PGC-1alpha.


title: MGU74Bv2_day3_PGC1a_rep1

description: Gene expression data from cells on day3 after transduction with PGC-1alpha.


title: MGU74Bv2_day1_PGC1a_rep3

description: Gene expression data from cells on day1 after transduction with PGC-1alpha.


title: MGU74Bv2_day3_PGC1a_rep2


title: MGU74Bv2_day3_GFP_rep1


title: 2003-12-02 Cold

source_name: THP-1 cells in culture x 24 hours at 32oC

label_protocol: Affmetrix

treatment_protocol: See Sonna et al., The effect of moderate hypothermia on gene expression by THP-1 cells: A cDNA microarray study.  Physiological Genomics 2006, submitted

tag: THP-1 Cells exposed to control (37oC) or hypothermic (32oC) conditions for 24 hours


title: MGU74Bv2_day2_GFP_rep1


title: MGU74Bv2_day3_PGC1a_rep3


title: MGU74Bv2_day2_PGC1a_rep1


title: MGU74Bv2_day2_GFP_rep2


title: MGU74Bv2_day3_GFP_rep2


title: MGU74Bv2_day1_GFP_rep3

description: Gene expression data from cells on day1 after transduction with GFP.


title: MGU74Bv2_day2_PGC1a_rep2


title: MGU74Bv2_day0_none_rep1

description: Gene expression data from cells on day 0, before transduction with either PGC-1a or GFP.


title: MGU74Bv2_day0_none_rep3


title: MGU74Bv2_day1_GFP_rep1


title: MGU74Cv2_day3_PGC1a_rep2


title: MGU74Cv2_day3_GFP_rep2


title: MGU74Cv2_day3_GFP_rep1


title: MGU74Bv2_day1_PGC1a_rep1


title: MGU74Cv2_day3_PGC1a_rep3


title: MGU74Bv2_day1_GFP_rep2


title: MGU74Bv2_day1_PGC1a_rep2


title: MGU74Bv2_day0_none_rep2


title: MGU74Cv2_day2_PGC1a_rep3


title: MGU74Cv2_day3_GFP_rep3


title: MGU74Cv2_day3_PGC1a_rep1


title: MGU74Cv2_day2_PGC1a_rep2


title: MGU74Cv2_day2_PGC1a_rep1


title: MGU74Cv2_day2_GFP_rep3


title: MGU74Cv2_day2_GFP_rep2


title: MGU74Cv2_day2_GFP_rep1


title: MGU74Cv2_day1_PGC1a_rep2


title: MGU74Cv2_day1_PGC1a_rep3


title: MGU74Cv2_day0_none_rep3


title: MGU74Cv2_day0_none_rep2


title: MGU74Cv2_day1_GFP_rep3


title: MGU74Cv2_day1_PGC1a_rep1


title: MGU74Cv2_day1_GFP_rep2


title: MGU74Cv2_day1_GFP_rep1


title: MGU74Av2_day3_PGC1a_rep1


title: MGU74Cv2_day0_none_rep1


title: MGU74Av2_day2_PGC1a_rep2


title: MGU74Av2_day2_PGC1a_rep3


title: MGU74Av2_day3_PGC1a_rep2


title: MGU74Av2_day2_GFP_rep2


title: MGU74Av2_day1_PGC1a_rep3


title: MGU74Av2_day3_GFP_rep1


title: MGU74Av2_day1_PGC1a_rep2


title: MGU74Av2_day1_GFP_rep1


title: MGU74Av2_day1_GFP_rep2


title: MGU74Av2_day3_PGC1a_rep3


title: MGU74Av2_day2_GFP_rep1


title: MGU74Av2_day2_GFP_rep3


title: MGU74Av2_day1_GFP_rep3


title: MGU74Av2_day3_GFP_rep2


title: MGU74Av2_day2_PGC1a_rep1


title: MGU74Av2_day0_none_rep3


title: MGU74Av2_day3_GFP_rep3


title: MGU74Av2_day1_PGC1a_rep1


title: MGU74Av2_day0_none_rep2


title: MGU74Av2_day0_none_rep1


title: Tiling wt

status: Public on Mar 06 2006

city: Stockholm

first: Karl

last: Ekwall

address: Alfred Nobels Alle 7

institute: Karolinska Inst

description: For the GeneChip® S. pombe Tiling Array from Affymetrix the DNA was amplified to obtain 5 micrograms of DNA then fragmented around 100 base pairs using DNAse I, labelled with biotin and hybridized according to Affymetrix recommendations (Lengronne et al., 2004). Antibodies specific for H3K9Ac, H3K14Ac, H4K5Ac,H4K12Ac, H4K16Ac (Suka et al., 2001) and H3cter (Ab1791, Abcam) were used for ChIP.

data_processing: ChIP-chip Affymetrix signals per chip normalized to the 50th percentile

organism: Schizosaccharomyces pombe

tag: CHIP IP wt sample


title: 1R2WB

status: Public on Mar 15 2006

city: Fargo

first: David

last: Horvath

state: ND

address: 1605 Albrecht Blvd

department: Agr. Research Service

institute: US Dept. Agriculture

hyb_protocol: Hybridization protocol was done according to chip manufacturers specifications (The Schnable Laboratory, Iowa State University)

scan_protocol: Arrays were scanned using an Affy428 scanner and Jaguar software.

data_processing: Raw signal intensities were log transformed and loess normalized using GeneMaths XT software (no background subtraction). The A-values (square root of the product of the log2 of the intensities for both channels) were calculated for each spot. Spots that had A-values of less than the average plus one standard deviation of the A-values of the empty spots were deleted from the data set.

organism: Zea mays

source_name: Weedy sample 2

label_protocol: Labeled cDNA was prepared from the 30 ug of total RNA using the Alexa Fluor cDNA labeling kit (Invitrogen) according to manufacture’s protocols.

growth_protocol: Plants were grown in field conditions with no supplemental water or fertilizer.

extract_protocol: The Pine Tree extraction procedure was used to extract RNA. Chang, S., J. Puryear, and J. Cairney. 1993. A simple and efficient method for isolating RNA from pine trees. Plant Mol. Biol. Rep. 11:113-116.

treatment_protocol: Material was frozen in liquid N2 in the field at harvest.

tag: Maize (cultivar DKC46-22 planted at density of 7 plants/m2 in Aurora, SD on a Brandt silty clay loam soil) was grown to the 11-13 leaf stage in the presence of velvetleaf (Abutilon theophrasti) planted on the same day and thinned to density of ~4 weeds/m2. Field plots were fertilized with urea broadcast at 224 kg N ha-1 after planting. 3-4 inches of leaf blade from the tip of the top fully expanded leaf was collected from 4 plants in the plot and the material was pooled. Plant material was collected between 2-3pm on July 11 2005 (just prior to a thunderstorm).

source_name: Control Sample 1

tag: Maize (cultivar DKC46-22 planted at density of 7 plants/m2 in Aurora, SD on a Brandt silty clay loam soil) was grown to the 12-14 leaf stage with broadleaf weed controlled by hand cultivation. Field plots were fertilized with urea broadcast at 224 kg N ha-1 after planting. 3-4 inches of leaf blade from the tip of the top fully expanded leaf was collected from 4 plants in the plot and the material was pooled. Plant material was collected between 2-3pm on July 11 2005 (just prior to a thunderstorm).


title: CS-022

status: Public on Feb 21 2006

city: Rahway

first: Olivia

last: Fong

state: NJ

department: Molecular Profiling

institute: Merck & Co.

description:
Chronic Myelogenous Leukemia
type: chronic
blast count: NaN
Center code: 5
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 1

source_name: CP Pool


title: CS-024

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: NaN
Center code: 5
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: CS-025


title: CP-198

description:
Chronic Myelogenous Leukemia
type: chronic
blast count: 1
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: CS-021


title: CP-179


title: CS-019


title: CS-026


title: CP-204


title: CP-150

description:
Chronic Myelogenous Leukemia
type: chronic
blast count: 1
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: CS-015


title: CS-027


title: CS-023


title: CP-148


title: CP-200


title: CP-140


title: CP-146


title: CP-144


title: CP-190


title: CP-194


title: CP-197


title: CP-191


title: CP-147


title: CP-149


title: CS-017


title: CP-187


title: CS-018


title: CP-141


title: CP-131


title: CS-014


title: CS-008


title: CP-092


title: CS-006


title: CP-085


title: BC-919997

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 14
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920001

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 80
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: CS-011


title: CP-084


title: CP-067


title: BC-920091

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 71
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: CP-020


title: CP-043


title: CP-019


title: CP-021


title: CP-037


title: CS-004


title: BC-047

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 70
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: CP-090


title: CS-002


title: CP-068


title: CP-069


title: CS-010


title: BC-048

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 50
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: CS-012


title: CP-042


title: CP-022


title: CP-066


title: CP-030


title: CP-025


title: CP-023


title: CS-005


title: CP-082


title: CP-017


title: CP-053


title: CP-124


title: CP-024


title: BC-036

description:
Chronic Myelogenous Leukemia
type: accelerated phase
blast count: 16
Center code: 4
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-031

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 92
Center code: 4
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-029

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 61
Center code: 4
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920086

description:
Chronic Myelogenous Leukemia
type: blast crisis remission
blast count: 1
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: CP-001


title: BC-042

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 95
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-030

description:
Chronic Myelogenous Leukemia
type: accelerated phase
blast count: 5
Center code: 4
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-044

description:
Chronic Myelogenous Leukemia
type: blast crisis remission
blast count: 5
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-046


title: BC-041

description:
Chronic Myelogenous Leukemia
type: unknown
blast count: NaN
Center code: 3
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-037

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 37
Center code: 3
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920084

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 65
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-038

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 71
Center code: 3
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-043


title: BC-033

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 30
Center code: 4
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-025


title: BC-022


title: BC-920063

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 60
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-039

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 65
Center code: 3
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920062

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 90
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-027

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 51
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920064

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 96
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920026

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 85
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920022

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 80
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920053

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 88
Center code: 6
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: AP-920039

description:
Chronic Myelogenous Leukemia
type: accelerated phase
blast count: 10
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920058

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 50
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: AP-920050

description:
Chronic Myelogenous Leukemia
type: accelerated phase
blast count: 13
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920018


title: BC-920016

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 98
Center code: 2
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920013


title: AP-018


title: AP-017

description:
Chronic Myelogenous Leukemia
type: ap-cyto
blast count: 1
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920025


title: AP-920051

description:
Chronic Myelogenous Leukemia
type: accelerated phase
blast count: 1
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: BC-920049

description:
Chronic Myelogenous Leukemia
type: blast crisis
blast count: 92
Center code: 6
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: AP-015


title: AP-007


title: AP-005

description:
Chronic Myelogenous Leukemia
type: accelerated phase
blast count: 20
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: CD34-920082

description:
Chronic Myelogenous Leukemia
type: cd34
blast count: NaN
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: AP-001

description:
Chronic Myelogenous Leukemia
type: ap-cyto
blast count: 3
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: AP-009

description:
Chronic Myelogenous Leukemia
type: ap-cyto
blast count: 9
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: CD34-006


title: AP-013


title: AP-010


title: CD34-005


title: AP-019


title: AP-002

description:
Chronic Myelogenous Leukemia
type: ap-cyto
blast count: 8
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: CD34-004


title: END_Subject 3_48H vs PRE

status: Public on Feb 17 2006

city: Ottawa

first: Douglas

middle: Joseph

last: Mahoney

state: ON

address: 401 Smyth Rd

department: Apoptosis Research Center

country: Canada

institute: CHEO Research Institute

description: Skeletal muscle biopsies were taken from the vastus lateralis before (baseline) or 48H after 75 min of high-intensity cycilng. Total RNA was extracted and amplified using a MessageAmp aRNA Linear Amplification Kit. Amplified RNA was converted to cDNA, labeled with either Cy3 or Cy5 and hybridized to our arrays (Genisphere, Kit 350RP). For each array, we used 976 buffer controls to differentiate signal from noise. Chips were scanned using a Packard Bioscience scanner (Hewlett Packard), ScanArray Express software (version 1.1), a PMT laser setting of 75, and power of 80.

data_processing: TIFF files were analyzed using Genepix 4, using median values for each spot. The data was LOWESS-normalized using GeneTraffic software (Iobion).

source_name: 48H Post-END exercise

tag: 48H Sample

source_name: Baseline Sample

tag: Baseline Sample


title: AP-008

description:
Chronic Myelogenous Leukemia
type: accelerated phase
blast count: 5
Center code: 1
Note: Center code == 5 not used for disease phase analysis
imatinib analysis: 0


title: END_Subject 4_48H vs PRE


title: END_Subject 1_48H vs PRE


title: END_Subject 3_3H vs PRE

description: Skeletal muscle biopsies were taken from the vastus lateralis before (baseline) or 3H after 75 min of high-intensity cycilng. Total RNA was extracted and amplified using a MessageAmp aRNA Linear Amplification Kit. Amplified RNA was converted to cDNA, labeled with either Cy3 or Cy5 and hybridized to our arrays (Genisphere, Kit 350RP). For each array, we used 976 buffer controls to differentiate signal from noise. Chips were scanned using a Packard Bioscience scanner (Hewlett Packard), ScanArray Express software (version 1.1), a PMT laser setting of 75, and power of 80.

source_name: 3H Post-END exercise

tag: 3H Sample


title: END_Subject 2_48H vs PRE

tag: Baseline sample


title: END_Subject 1_3H vs PRE


title: CD34-003


title: END_Subject 2_3H vs PRE


title: END_Subject 4_3H vs PRE

description: Skeletal muscle biopsies were taken from the vastus lateralis before (baseline) or 3H after 75 min of high-intensity cycilng.  Total RNA was extracted and amplified using a MessageAmp aRNA Linear Amplification Kit.  Amplified RNA was converted to cDNA, labeled with either Cy3 or Cy5 and hybridized to our arrays (Genisphere, Kit 350RP).  For each array, we used 976 buffer controls to differentiate signal from noise.  Chips were scanned using a Packard Bioscience scanner (Hewlett Packard), ScanArray Express software (version 1.1), a PMT laser setting of 75, and power of 80.

data_processing: TIFF files were analyzed using Genepix 4, using median values for each spot.  The data was LOWESS-normalized using GeneTraffic software (Iobion).


title: WT_16h:Blank_16h - mAdb ID 54161

status: Public on Feb 10 2006

city: Bethesda

first: Naoto

last: Yoshizuka

institute: NCI

description:
mAdb experiment ID: 54161
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 16 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 16
SAMPLE: WT_16h:Blank_16h


title: CD34-001


title: WT_16h:Blank_16h - mAdb ID 54154

description:
mAdb experiment ID: 54154
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 16 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 16
SAMPLE: WT_16h:Blank_16h


title: WT_24h:Blank_24h - mAdb ID 54159

description:
mAdb experiment ID: 54159
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 24 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 24
SAMPLE: WT_24h:Blank_24h


title: WT_12h:Blank_12h - mAdb ID 54153

description:
mAdb experiment ID: 54153
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 12 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 12
SAMPLE: WT_12h:Blank_12h


title: WT_4h:Blank_4h - mAdb ID 54149

description:
mAdb experiment ID: 54149
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 4 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 4
SAMPLE: WT_4h:Blank_4h


title: WT_8h:Blank_8h - mAdb ID 54151

description:
mAdb experiment ID: 54151
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 8 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 8
SAMPLE: WT_8h:Blank_8h


title: WT_1h:Blank_1h - mAdb ID 54146

description:
mAdb experiment ID: 54146
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 1 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 1
SAMPLE: WT_1h:Blank_1h


title: F72A/R73A_24h:Blank_24h - mAdb ID 54951

description:
mAdb experiment ID: 54951
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 24 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 24
SAMPLE: F72A/R73A_24h:Blank_24h


title: WT_6h:Blank_6h - mAdb ID 54150

description:
mAdb experiment ID: 54150
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 6 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 6
SAMPLE: WT_6h:Blank_6h


title: WT_24h:Blank_24h - mAdb ID 54156

description:
mAdb experiment ID: 54156
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 24 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 24
SAMPLE: WT_24h:Blank_24h


title: WT_2h:Blank_2h - mAdb ID 54148

description:
mAdb experiment ID: 54148
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 2 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 2
SAMPLE: WT_2h:Blank_2h


title: WT_24h:Blank_24h - mAdb ID 51004

description:
mAdb experiment ID: 51004
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 24 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 24
SAMPLE: WT_24h:Blank_24h


title: WT_16h:Blank_16h - mAdb ID 51003

description:
mAdb experiment ID: 51003
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 16 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 16
SAMPLE: WT_16h:Blank_16h


title: WT_0h:Blank_0h - mAdb ID 54324

description:
mAdb experiment ID: 54324
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 0 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: none
treatment_time (hrs): 0
SAMPLE: WT_0h:Blank_0h


title: WT_4h:Blank_4h - mAdb ID 50999

description:
mAdb experiment ID: 50999
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 4 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 4
SAMPLE: WT_4h:Blank_4h


title: F72A/R73A_24h:Blank_24h - mAdb ID 51545

description:
mAdb experiment ID: 51545
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 24 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p19-110403
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 24
SAMPLE: F72A/R73A_24h:Blank_24h


title: F72A/R73A_12h:Blank_12h - mAdb ID 54949

description:
mAdb experiment ID: 54949
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 12 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 12
SAMPLE: F72A/R73A_12h:Blank_12h


title: F72A/R73A_12h:Blank_12h - mAdb ID 51543

description:
mAdb experiment ID: 51543
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 12 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p19-110403
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 12
SAMPLE: F72A/R73A_12h:Blank_12h


title: F72A/R73A_16h:Blank_16h - mAdb ID 51544

description:
mAdb experiment ID: 51544
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 16 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p19-110403
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 16
SAMPLE: F72A/R73A_16h:Blank_16h


title: F72A/R73A_8h:Blank_8h - mAdb ID 54948

description:
mAdb experiment ID: 54948
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 8 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 8
SAMPLE: F72A/R73A_8h:Blank_8h


title: F72A/R73A_16h:Blank_16h - mAdb ID 54950

description:
mAdb experiment ID: 54950
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 16 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 16
SAMPLE: F72A/R73A_16h:Blank_16h


title: WT_8h:Blank_8h - mAdb ID 51001

description:
mAdb experiment ID: 51001
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 8 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 8
SAMPLE: WT_8h:Blank_8h


title: R80A_24h:Blank_24h - mAdb ID 51483

description:
mAdb experiment ID: 51483
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 24 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 24
SAMPLE: R80A_24h:Blank_24h


title: F72A/R73A_8h:Blank_8h - mAdb ID 51542

description:
mAdb experiment ID: 51542
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 8 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p19-110403
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 8
SAMPLE: F72A/R73A_8h:Blank_8h


title: WT_6h:Blank_6h - mAdb ID 51000

description:
mAdb experiment ID: 51000
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 6 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 6
SAMPLE: WT_6h:Blank_6h


title: R80A_16h:Blank_16h - mAdb ID 51482

description:
mAdb experiment ID: 51482
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 16 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 16
SAMPLE: R80A_16h:Blank_16h


title: WT_2h:Blank_2h - mAdb ID 50998

description:
mAdb experiment ID: 50998
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 2 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 2
SAMPLE: WT_2h:Blank_2h


title: WT_12h:Blank_12h - mAdb ID 51002

description:
mAdb experiment ID: 51002
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 12 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 12
SAMPLE: WT_12h:Blank_12h


title: WT_1h:Blank_1h - mAdb ID 50997

description:
mAdb experiment ID: 50997
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 1 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 1
SAMPLE: WT_1h:Blank_1h


title: WT_0h:Blank_0h - mAdb ID 50996

description:
mAdb experiment ID: 50996
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 0 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: none
treatment_time (hrs): 0
SAMPLE: WT_0h:Blank_0h


title: F72A/R73A_6h:Blank_6h - mAdb ID 54947

description:
mAdb experiment ID: 54947
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 6 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 6
SAMPLE: F72A/R73A_6h:Blank_6h


title: F72A/R73A_6h:Blank_6h - mAdb ID 51541

description:
mAdb experiment ID: 51541
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 6 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p19-110403
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 6
SAMPLE: F72A/R73A_6h:Blank_6h


title: R80A_8h:Blank_8h - mAdb ID 51488

description:
mAdb experiment ID: 51488
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 8 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 8
SAMPLE: R80A_8h:Blank_8h


title: R80A_12h:Blank_12h - mAdb ID 51481

description:
mAdb experiment ID: 51481
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 12 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 12
SAMPLE: R80A_12h:Blank_12h


title: WT_24h:Blank_24h - mAdb ID 49527

description:
mAdb experiment ID: 49527
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 24 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 24
SAMPLE: WT_24h:Blank_24h


title: F72A/R73A_4h:Blank_4h - mAdb ID 54946

description:
mAdb experiment ID: 54946
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 4 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 4
SAMPLE: F72A/R73A_4h:Blank_4h


title: WT_16h:Blank_16h - mAdb ID 49526

description:
mAdb experiment ID: 49526
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 16 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 16
SAMPLE: WT_16h:Blank_16h


title: R80A_8h:Blank_8h - mAdb ID 51480

description:
mAdb experiment ID: 51480
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 8 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 8
SAMPLE: R80A_8h:Blank_8h


title: F72A/R73A_4h:Blank_4h - mAdb ID 51540

description:
mAdb experiment ID: 51540
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 4 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p19-110403
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 4
SAMPLE: F72A/R73A_4h:Blank_4h


title: F72A/R73A_2h:Blank_2h - mAdb ID 54945

description:
mAdb experiment ID: 54945
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 2 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 2
SAMPLE: F72A/R73A_2h:Blank_2h


title: WT_8h:Blank_8h - mAdb ID 49524

description:
mAdb experiment ID: 49524
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 8 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 8
SAMPLE: WT_8h:Blank_8h


title: R80A_6h:Blank_6h - mAdb ID 51479

description:
mAdb experiment ID: 51479
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 8 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 6
SAMPLE: R80A_6h:Blank_6h


title: WT_12h:Blank_12h - mAdb ID 49525

description:
mAdb experiment ID: 49525
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 12 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 12
SAMPLE: WT_12h:Blank_12h


title: R80A_2h:Blank_2h - mAdb ID 51477

description:
mAdb experiment ID: 51477
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 2 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 2
SAMPLE: R80A_2h:Blank_2h


title: WT_4h:Blank_4h - mAdb ID 49505

description:
mAdb experiment ID: 49505
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 4 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 4
SAMPLE: WT_4h:Blank_4h


title: F72A/R73A_1h:Blank_1h - mAdb ID 51538

description:
mAdb experiment ID: 51538
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 1 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p19-110403
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 1
SAMPLE: F72A/R73A_1h:Blank_1h


title: F72A/R73A_1h:Blank_1h - mAdb ID 54944

description:
mAdb experiment ID: 54944
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 1 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 1
SAMPLE: F72A/R73A_1h:Blank_1h


title: R80A_0h:Blank_0h - mAdb ID 51485

description:
mAdb experiment ID: 51485
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 0 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: none
treatment_time (hrs): 0
SAMPLE: R80A_0h:Blank_0h


title: R80A_1h:Blank_1h - mAdb ID 51476

description:
mAdb experiment ID: 51476
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 1 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 1
SAMPLE: R80A_1h:Blank_1h


title: WT_0h:Blank_0h - mAdb ID 49501

description:
mAdb experiment ID: 49501
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 0 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: none
treatment_time (hrs): 0
SAMPLE: WT_0h:Blank_0h


title: F72A/R73A_0h:Blank_0h - mAdb ID 51537

description:
mAdb experiment ID: 51537
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 0 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p19-110403
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: none
treatment_time (hrs): 0
SAMPLE: F72A/R73A_0h:Blank_0h


title: R80A_0h:Blank_0h - mAdb ID 51475

description:
mAdb experiment ID: 51475
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 0 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: none
treatment_time (hrs): 0
SAMPLE: R80A_0h:Blank_0h


title: R80A_4h:Blank_4h - mAdb ID 51478

description:
mAdb experiment ID: 51478
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 4 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 4
SAMPLE: R80A_4h:Blank_4h


title: F72A/R73A_2h:Blank_2h - mAdb ID 51539

description:
mAdb experiment ID: 51539
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 2 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p19-110403
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 2
SAMPLE: F72A/R73A_2h:Blank_2h


title: WT_2h:Blank_2h - mAdb ID 49504

description:
mAdb experiment ID: 49504
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 2 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 2
SAMPLE: WT_2h:Blank_2h


title: R80A_12h:Blank_12h - mAdb ID 56143

description:
mAdb experiment ID: 56143
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 12 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 12
SAMPLE: R80A_12h:Blank_12h


title: F72A/R73A_8h:Blank_8h - mAdb ID 56127

description:
mAdb experiment ID: 56127
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 8 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 8
SAMPLE: F72A/R73A_8h:Blank_8h


title: R80A_8h:Blank_8h - mAdb ID 56142

description:
mAdb experiment ID: 56142
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 8 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 8
SAMPLE: R80A_8h:Blank_8h


title: R80A_6h:Blank_6h - mAdb ID 56141

description:
mAdb experiment ID: 56141
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 6 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 6
SAMPLE: R80A_6h:Blank_6h


title: R80A_16h:Blank_16h - mAdb ID 56145

description:
mAdb experiment ID: 56145
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 16 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 16
SAMPLE: R80A_16h:Blank_16h


title: F72A/R73A_0h:Blank_0h - mAdb ID 54943

description:
mAdb experiment ID: 54943
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 0 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.2p26-012004
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: none
treatment_time (hrs): 0
SAMPLE: F72A/R73A_0h:Blank_0h


title: R80A_1h:Blank_1h - mAdb ID 51487

description:
mAdb experiment ID: 51487
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 1 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 1
SAMPLE: R80A_1h:Blank_1h


title: F72A/R73A_12h:Blank_12h - mAdb ID 56129

description:
mAdb experiment ID: 56129
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 12 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 12
SAMPLE: F72A/R73A_12h:Blank_12h


title: WT_1h:Blank_1h - mAdb ID 49502

description:
mAdb experiment ID: 49502
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 1 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 1
SAMPLE: WT_1h:Blank_1h


title: WT_6h:Blank_6h - mAdb ID 49507

description:
mAdb experiment ID: 49507
Flp-In TREx 293 cells stably transfected with wild type-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 6 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.1p13-061803
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 6
SAMPLE: WT_6h:Blank_6h


title: F72A/R73A_24h:Blank_24h - mAdb ID 56134

description:
mAdb experiment ID: 56134
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 24 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 24
SAMPLE: F72A/R73A_24h:Blank_24h


title: F72A/R73A_6h:Blank_6h - mAdb ID 56126

description:
mAdb experiment ID: 56126
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 6 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 6
SAMPLE: F72A/R73A_6h:Blank_6h


title: F72A/R73A_1h:Blank_1h - mAdb ID 56123

description:
mAdb experiment ID: 56123
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 1 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 1
SAMPLE: F72A/R73A_1h:Blank_1h


title: F72A/R73A_2h:Blank_2h - mAdb ID 56124

description:
mAdb experiment ID: 56124
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 2 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 2
SAMPLE: F72A/R73A_2h:Blank_2h


title: R80A_1h:Blank_1h - mAdb ID 56138

description:
mAdb experiment ID: 56138
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 1 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 1
SAMPLE: R80A_1h:Blank_1h


title: F72A/R73A_4h:Blank_4h - mAdb ID 56125

description:
mAdb experiment ID: 56125
Flp-In TREx 293 cells stably transfected with F72A/R73A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 4 hrs of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 4
SAMPLE: F72A/R73A_4h:Blank_4h


title: R80A_1h:Blank_1h - mAdb ID 56657

description:
mAdb experiment ID: 56657
Flp-In TREx 293 cells stably transfected with R80A-Vpr versus Flp-In TREx 293 cells stably transfected with blank vector harvested after 1 hr of doxycycline treatment
Array Print: Hs-OperonV2-vB1.3p08-032904
cell_type: human embryonic kidney
cell_line: 293
Doxycycline treatment: 1 microgram/ml
treatment_time (hrs): 1
SAMPLE: R80A_1h:Blank_1h